• January 20, 2020

Tularaemia - Pipeline Review, H2 2019: Aradigm Corp, EpiVax Inc & Tetraphase Pharmaceuticals Inc - ResearchAndMarkets.com - Odessa American: Business

e-Edition Subscribe

Tularaemia - Pipeline Review, H2 2019: Aradigm Corp, EpiVax Inc & Tetraphase Pharmaceuticals Inc - ResearchAndMarkets.com

Print
Font Size:
Default font size
Larger font size

Posted: Thursday, January 9, 2020 10:01 am

DUBLIN--(BUSINESS WIRE)--Jan 9, 2020--

The "Tularaemia - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Tularaemia is an infection caused due to a bacterium called Francisella tularensis. Humans become infected mainly through the bite of arthropods, particularly ticks and mosquitoes, and through the skin, conjunctival sac or oropharyngeal mucosa, by direct contact with infected animals or animal materials and by ingestion of contaminated food or water or inhalation of contaminated dust or aerosols. Symptoms include skin ulcer, swollen and painful lymph glands, fever and chills. Treatment includes antibiotics and healthy lifestyle.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Tularaemia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Tularaemia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tularaemia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tularaemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 3 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Tularaemia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tularaemia (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Tularaemia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tularaemia (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tularaemia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tularaemia (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tularaemia (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tularaemia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

  • Introduction
  • Report Coverage
  • Tularaemia - Overview
  • Tularaemia - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Tularaemia - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Tularaemia - Companies Involved in Therapeutics Development
  • Appili Therapeutics Inc
  • Aradigm Corp
  • DynPort Vaccine Company LLC
  • EpiVax Inc
  • Tetraphase Pharmaceuticals Inc
  • Tularaemia - Drug Profiles
  • ATI-1701 - Drug Profile
  • ciprofloxacin - Drug Profile
  • NDBR-101 - Drug Profile
  • Small Molecules for Infectious Diseases - Drug Profile
  • TP-271 - Drug Profile
  • tularaemia [strain B] vaccine - Drug Profile
  • tularaemia vaccine - Drug Profile
  • tularemia vaccine - Drug Profile
  • Tularaemia - Dormant Projects
  • Tularaemia - Discontinued Products
  • Tularaemia - Product Development Milestones
  • Featured News & Press Releases

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/3b71vx

View source version on businesswire.com:https://www.businesswire.com/news/home/20200109005618/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 01/09/2020 11:01 AM/DISC: 01/09/2020 11:01 AM

http://www.businesswire.com/news/home/20200109005618/en

© 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Odessa, TX

Current Conditions

Cloudy
38°
Humidity: 64%
Winds: E at 2mph
Feels Like: 38°

Your Extended Forecast

Tomorrow

weather
High 54°/Low 38°
Clouds giving way to sun . Highs in the mid 50s and lows in the upper 30s.

tuesday

weather
High 51°/Low 42°
Windy, chance of late day showers. Highs in the low 50s and lows in the low 40s.

wednesday

weather
High 66°/Low 37°
Mostly sunny. Highs in the mid 60s and lows in the upper 30s.
Online Features

Pet Central

pets

Having a pet is a lot of responsibility, and we’ll help by giving you lots of tips and tricks! More >>

Fitness

Fitness

Our fitness articles will help teach you how to work out with gym- and home-based exercises. More >>

Crosswords

Crosswords

Enjoy the crosswords challenge in our free daily puzzles, from the harder Sunday crossword to the quicker daily. More >>

Sudoku

Sudoku

Every Sudoku has a unique solution that can be reached logically. Enter numbers into the blank spaces so that each row, column and 3x3 box contains the numbers 1 to 9. More >>




  • ALL-ACCESS: Subscribe to our e-edition and premium website at myoaoa.com.
    You can read your daily newspaper without taking a walk to the driveway.
    Look back at yesterday's newspaper, or issues from months ago with our archive feature.
    Call circulation at 432-337-7314 to sign up today.